Genes, disease and medicine

British Journal of Clinical Pharmacology

Volumn 42, Issue 6, 1996, Pages 683-695

  Dykes, Colin W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

drug development; ELSI; gene therapy; genetic screening; pharmacogenetics; targeted therapy

Indexed keywords

ANTIDEPRESSANT AGENT; DIAZEPAM; IMIPRAMINE; NEUROLEPTIC AGENT; OMEPRAZOLE; PROPRANOLOL;

CLINICAL TRIAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG METABOLISM; DRUG SAFETY; GENE TECHNOLOGY; GENE THERAPY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MUTATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0029853840     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.00473.x     Document Type: Review

References (53)

1. Lifton R. Molecular genetics of human blood pressure variation. Science 1996; 272: 676-680.
2. Aitman TJ, Todd JA. Molecular genetics of diabetes mellitus. Baillieres Clin Endocrinol Metab 1995; 9: 631-56.
3. Thomson G. HLA disease associations: models for the study of complex human genetic disorders. Crit Rev Clin Lab Sci 1995; 32: 183-219.
4. Sandberg AA, Chen Z. Cancer cytogenetics and molecular genetics: detection and therapeutic strategy. In Vivo 1994; 8: 807-18.
5. Klein J, O'Huigin C. MHC polymorphism and parasites. Philos Trans R Soc Land B Biol Sci 1994; 346: 351-7.
6. The Huntington's disease Collaborative Research Group. A novel gene containing a triplet repeat that is expanded and unstable on Huntington's Disease chromosomes. Cell 1993; 72: 971-983.
7. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994; 265: 2037-2048.
8. Goate A, Chartier HM, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
9. Sherrington R, Rogaev E, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease Nature 1995; 375: p754-760.
10. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-977.
11. Miki Y, Swensen J, Shattuck-Eidens DA, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
12. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-792.
13. Collins F, Galas D. A new five-year plan for the U.S. Human Genome Project. Science 1993; 262: 43.
14. Murray JC, Beutow KH, Weber JL, et al. A comprehensive human linkage map with centimorgan density. Science 1994; 265: 2049-2054.
15. Marshall E. A strategy for sequencing the genome 5 years early. Science 1995; 267: 783-784.
16. Anon. Capitalizing on the genome. Nature Genet 1996; 13: 1-5.
17. Boguski MS, Schuler GD. Establishing a human transcript map. Nature Genet 1995; 10; 369-71.
18. Anon. Biopharmaceuticals market growing fast. Marketletter 1994, Issue of June 13th, 19.
19. Shamel RE, and Keough M, Sales of US biopharmaceutical products expected to triple by 2004. Genet Eng News 1995; 15: 6.
20. Fleischmann RD, Adams MD, White O, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995; 269: 496-512.
21. Miller, A.D. Human gene therapy comes of age. Nature 1992; 357: 455-460.
22. Friedmann T. Human gene therapy-an immature genie, but certainly out of the bottle. Nature Medicine 1996; 2: 144-147.
23. Crystal RG. Transfer of genes to humans: Early lessons and obstacles to success. Science 1995; 270: 404-410.
24. Hodgson CP. The vector void in gene therapy. Bio/technology 1995; 13: 222-225.
25. Treco DA, Selden RF. Non-viral gene therapy. Molecular Medicine Today 1995; 1: 314-332.
26. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Therapy 1995; 2: 710-722.
27. Gunzburg WH, Salmons B. Virus vector design in gene therapy. Molecular Medicine Today 1995; 1: 410-417.
28. Blau HM, Springer ML. Gene therapy-a novel form of drug delivery. New Eng J Med 1995; 333: 1204-1207.
29. Wagner JA, Chao AC, Gardner P. Molecular strategies for therapy of cystic fibrosis. Ann Rev Pharmacol Toxicol 1995; 35: 257-276.
30. Sisodia SS, Price DL. Role of the β-amyloid protein in Alzheimer's Disease. FASEB J 1995; 9: 366-370.
31. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's Disease. Ann Rev Neurosci 1996; 19: 53-77.
32. Levitan D, Greenwald I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 1995; 377: 351-4.
33. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: Role of Angiotensinogen. Cell 1992; 71: 169-180.
34. Kim S, Krege JH, Kluckman KD, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U.S.A. 1995; 92: 2735-2739.
35. Shimkets RA, Watnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the β-adrenoceptor subunit of the epithelial sodium channel. Cell 1994; 79: 407-414.
36. Hannson JH, Nelson-Williams C, Suzuki H, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nature Genet 1995; 11: 76-82.
37. Strautnieks SS, Thompson RJ, Hanukoglu A, et al. Localisation of pseudohypoaldosteronism genes to chromosome 16p12.2-13.11 and 12p13.1-pter by homozygosity mapping. Hum Mol Genet 1996; 5: 293-299.
38. Chang SS, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epithelial sodium channel cause wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nature Genet 1996; 12: 248-53.
39. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29: 192-209.
40. Johansson I, Oscarsson M, Yue QY, et al. Genetic analysis of the Chinese CYP2D6 locus. Characterisation of mutant genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-459.
41. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine-a case report with implication for treatment with nortryptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 478-480.
42. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U.S.A. 1993; 90: 11825-11829.
43. De Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of S-mephentoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
44. Mullis K, Faloona F, Scharf S, et al. Specific amplification of DNA in vitro: The polymerase chain reaction. Cold Spring Harbor Symposia on Quantitative Biology 1986; 51: Molecular Biology of Homo Sapiens XXV + 702P.(Part 1); XV + 527P.(Part 2).
45. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491.
46. Nickerson DA, Kaiser R, Lappin S, et al. Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay. Proc Natl Acad Sci U.S.A. 1990; 87: 8923-8927.
47. Patrizio P, Zielenski J. Congenital absence of the vas deferens: a mild form of cystic fibrosis. Mol Med Today 1996; 2: 24-31.
48. Hubbard R, Lewontin RC. Pitfalls of genetic testing. N Engl J Med 1996: 334; 1192-1193.
49. Lipshutz RJ, Morris D, Chee M, et al. Using oligonucleotide probe arrays to access genetic diversity. Biotechniques 1995; 19: 442-447.
50. Drmanac R, Drmanac S, Strezoska Z, et al. DNA sequence determination by hybridization: a strategy for efficient large-scale sequencing. Science 1993; 260: 1649-1652.
51. Beardsley T. Trends in human genetics: Vital Data. Scientific American 1996: 274: 76-81.
52. Dean M, Santis G. Heterogeneity in the severity of cystic fibrosis and the role of CFTR gene mutations. Hum Genet 1994; 93: 364-368.
53. Nowak, R. Genetic testing set for takeoff. Science 1994; 265: 464-467.